DARA
Showing 1 - 25 of 137
Multiple Myeloma Trial (Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT
Not yet recruiting
- Multiple Myeloma
- Dara-VRd intensification, Dara-R maintenance
- +4 more
- (no location specified)
Dec 13, 2022
Multiple Myeloma, Renal Failure Trial in Augusta (Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide,
Not yet recruiting
- Multiple Myeloma
- Renal Failure
- Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
-
Augusta, GeorgiaGeorgia Cancer Center-Augusta University
Nov 16, 2023
Relapsed or Refractory Multiple Myeloma Trial (Daratumumab, Pomalidomide)
Withdrawn
- Relapsed or Refractory Multiple Myeloma
- (no location specified)
Jan 26, 2023
AL Amyloidosis Trial (procedure, drug, other)
Not yet recruiting
- AL Amyloidosis
- Autologous Hematopoietic Stem Cell Transplantation
- +15 more
- (no location specified)
Aug 28, 2023
Multiple Myeloma Trial in Torino (Velcade, Melphalan, Prednisone)
Recruiting
- Multiple Myeloma
- Velcade
- +5 more
-
Torino, TO, ItalyDipartimento di Biotecnologie Molecolari e Scienze per la Salute
May 25, 2022
Maintenance With Bortezomib Plus Daratumumab After Induction
Recruiting
- Multiple Myeloma
- Non-eligible for Autologous Stem Cell Transplantation (ASCT)
-
Arganda Del Rey, Spain
- +31 more
Sep 15, 2022
Newly Diagnosed Multiple Myeloma Trial in New York (Daratumumab, Bortezomib, Lenalidomide)
Recruiting
- Newly Diagnosed Multiple Myeloma
- Daratumumab
- +4 more
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Dec 29, 2022
Plasma Cell Myeloma Trial in Philadelphia (Daratumumab and Hyaluronidase-fihj, Questionnaire Administration, Quality-of-Life
Not yet recruiting
- Plasma Cell Myeloma
- Daratumumab and Hyaluronidase-fihj
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Aug 19, 2022
Multiple Myeloma Trial (Dara-SC, Blood for research assessments, Bone marrow for research assessments)
Withdrawn
- Multiple Myeloma
- Dara-SC
- +2 more
- (no location specified)
Jan 6, 2022
Aplastic Anemia, Bone Marrow Failure Syndrome Trial in Memphis (drug, radiation, device, biological)
Recruiting
- Aplastic Anemia
- Bone Marrow Failure Syndrome
- Anti-Thymocyte Globulin (Rabbit)
- +8 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Aug 26, 2022
High-risk Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Daratumumab, Bortezomib, Lenalidomide)
Recruiting
- High-risk Smoldering Multiple Myeloma
- Multiple Myeloma
- Daratumumab
- +3 more
-
Boston, Massachusetts
- +1 more
Oct 18, 2021
Newly Diagnosed Multiple Myeloma Trial (Daratumumab)
Not yet recruiting
- Newly Diagnosed Multiple Myeloma
- (no location specified)
Oct 10, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Columbus (Bortezomib, Daratumumab and Hyaluronidase-fihj,
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 30, 2021
Sentinel Lymph Node Biopsy in Early-Stage, Palpable
Recruiting
- Breast Cancer
- Breast surgery
-
Hartford, Connecticut
- +9 more
Jan 27, 2023
Multiple Myeloma Trial in Worldwide (Melphalan flufenamide (Melflufen), Dexamethasone, Bortezomib)
Terminated
- Multiple Myeloma
- Melphalan flufenamide (Melflufen)
- +3 more
-
Boston, Massachusetts
- +15 more
Mar 4, 2022
Multiple Myeloma Trial in Miami (Teclistamab, Talquetamab, Daratumumab SC)
Not yet recruiting
- Multiple Myeloma
- Teclistamab
- +2 more
-
Miami, FloridaUniversity of Miami
Oct 20, 2023
High-Risk de Novo Multiple Myeloma Trial in Spain (Daratumumab, Bortezomib, Lenalidomide)
Not yet recruiting
- High-Risk de Novo Multiple Myeloma
- Daratumumab
- +5 more
-
Badalona, Spain
- +9 more
Apr 27, 2023
Multiple Myeloma Trial in Taiyuan (CD19-CD22 CAR-T cells)
Recruiting
- Multiple Myeloma
- CD19-CD22 CAR-T cells
-
Taiyuan, Shanxi, ChinaHematology Department of ShanXi Cancer Hospital
Jan 17, 2021
Lymphoma, B-Cell Trial in Taiyuan (CD19-CD22 CAR-T cells)
Recruiting
- Lymphoma, B-Cell
- CD19-CD22 CAR-T cells
-
Taiyuan, Shanxi, ChinaHematology Department of ShanXi Cancer Hospital
Jan 17, 2021
Acute Lymphocytic Leukemia, B-Cell Trial in Taiyuan (CD19-CD22 CAR-T cells)
Recruiting
- Acute Lymphocytic Leukemia, B-Cell
- CD19-CD22 CAR-T cells
-
Taiyuan, Shanxi, ChinaHematology Department of ShanXi Cancer Hospital
Jan 17, 2021
Multiple Myeloma Trial in Worldwide (Carfilzomib 20 mg/m^2, Carfilzomib 70 mg/m^2, Dexamethasone 40 mg)
Active, not recruiting
- Multiple Myeloma
- Carfilzomib 20 mg/m^2
- +4 more
-
Gilbert, Arizona
- +107 more
Dec 20, 2022